A study to find out the best length of time between ocrelizumab doses for patients with relapsing remitting multiple sclerosis using a trial design with multiple groups and multiple stages
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Fields of Study & Subjects
Multiple Sclerosis Research Studies
Statistical Methods in Clinical Trials
Chronic Lymphocytic Leukemia Research
Publication details
- Journal / source
- http://isrctn.com/
- Publication date
- 26 March 2026
- Language
- EN